Serum Amyloid A Level in Egyptian Children with Familial Mediterranean Fever

Table 3

Demographic and clinical characteristics of studied patients stratified according to the level of SAA.

	Serum amyloid A level (SAA)		value
	Low (<30 mg/L)	High (>30 mg/L)
Sex
Male	12/36 (33.3%)	24/36 (66.7%)	0.018
Female	3/35 (8.6%)	32/35 (91.4%)
Positive consanguinity	5/25 (20%)	20/25 (80%)	1.0
Family history of FMF	2/6 (33.3%)	4/6 (66.7%)	0.6
Family history of renal disease	1/6 (16.7%)	5/6 (83.3%)	1.0
Age at disease onset (year)	4.87 ± 3.04	4.98 ± 2.85
Age at disease diagnosis (year)	6.98 ± 3.32	7.14 ± 3.43
Duration between the disease onset and diagnosis (year)	1.90 ± 1.93	2.12 ± 2.17
Disease duration (year)	3.97 ± 2.54	4.00 ± 2.90
Age at time of study (year)	8.78 ± 3.60	9.07 ± 3.73
Frequency of attacks/month	2.27 ± 2.95	3.08 ± 2.82
Duration of attacks (day)	1.30 ± 0.90	1.65 ± 1.73
MEFV mutation (HH)
Heterozygous	10/46 (21.7%)	36/46 (78.3%)	1.0
Compound heterozygous	2/13 (15.4%)	11/13 (84.6%)	0.72
Homozygous	3/12 (25%)	9/12 (75%)	0.71
Fever	13/64 (20.3%)	51/64 (79.7%)	0.63
Abdominal pain	15/70 (21.4%)	55/70 (78.6%)	1.0
Chest pain	10/49 (20.4%)	39/49 (79.6%)	1.0
Myalgia	4/28 (14.3%)	24/28 (85.7%)	0.37
Arthritis	8/25 (32%)	17/25 (68%)	0.13
Arthralgia	9/53 (17%)	44/53 (83.01%)	0.18
Rash	2/9 (22.2%)	7/9 (77.8%)	1.0
Testicular affection	2/4 (50%)	2/4 (50%)	0.59
Proteinuria	3/10 (30%)	7/10 (70%)	0.43
ESR (≥15 mm/Hg)	11/50 (22%)	39/50 (78%)
+ve CRP	6/22 (27.3%)	16/22 (72.7%)	0.53